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Introduction
Breast cancer is the most common cancer among 
women, accounting for about 30% of  all cancers [1]. 
The majority are sporadic, where as 5 to 10% are due 
to an inherited predisposition to breast and ovarian 
cancers, transmitted as an autosomal dominant form 
with incomplete penetrance [2, 3]. Germline mutations 
of  BRCA1 and BRCA2 genes are involved in nearly 
10% of  ovarian cancers and 3-5% of  breast cancers 
respectively [4, 5]. The two genes belong to a class of  
tumor suppressor genes that maintain genomic integrity 
to prevent uncontrolled proliferation of  tumor cells. 
They are also involved in DNA damage recognition, 
double-strand break repair, checkpoint control, 
transcription regulation and chromatin remodeling [6]. 
BRCA1 and BRCA2 are large genes containing 5,592 and 
11,385 nucleotides spread over approximately 100,000 
bases of  genomic DNA each [7]. More than 1880 
BRCA mutations are reported [8]. These mutations are 
distributed throughout the coding region and flanking 
intronic sequences, most are framshifts causing
Corresponding author:
Soukaina Guaoua
Département de génétique médicale
Institut National d’Hygiène, Avenue 
Ibn Batouta, B.P. 769 Rabat – Morocco.
Tel. +212 (0) 675283238.
 Fax. +212 (0) 537 77 20 67. 
E-mail:soukainaguaoua@gmail.com
a frameshift reading of  nonsense mutations or splice 
site alterations that lead to truncated proteins [9]. Breast 
cancer is a very rare disease in men, accounting for less 
than 1% of  all cancers [10]. BRCA2 mutations account 
for a significant proportion in both man breast cancer 
cases with or without a family history of  the disease 
[11, 12]. 
We report here a novel nonsense mutation of  BRCA2 
gene in a Moroccan man with breast cancer and family 
history of  the disease.
Case report
A 63 years-old man with breast cancer was referred for 
genetic counselling. The family had five other women 
with breast cancer, and three cases with prostate, liver 
and uterus cancers (Figure 1). 
One year before, he was diagnosed with infiltrating 
ductal carcinoma grade 2 of  18 mm diameter in his left 
breast. Hercept test (HER2) was negative, oestrogen and 
progesterone receptors were positive. The patient had 
no other associated diseases. Conservative tumorectomy 
was performed. He was treated by chemotherapy and 
local radiotherapy. Written informed consent was 
obtained from the patient prior to implementation of  
the genetic study reported here.
Genomic DNA was extracted from peripheral blood 
lymphocytes using salt extraction methods [13]. We 
chose to analyse firstly the exon 11 of  BRCA2 gene 
by bi-directional sequencing, because it’s the longest 
exon with the most reported mutations BIC (Breast 
Cancer Information Core): http://research.nhgri.nih.
gov/bic/ . Sequence variation was verified in a new 
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blood sample. The BRCA2 mutation was numbered 
according to GenBank accession number NM_000059, 
in which A in the AUG start codon has number 229. In 
silico prediction of  the functional consequence of  the 
nonsens variant was performed using, MutationTaster 
(http://www.mutationtaster.org/) [14] and SIFT 
(Sorting Intolerant From Tolerant): http://blocks.fhcrc.
org/sift/SIFT. html [15].
Figure 1: Family pedigree. Breast (BC), uterus (UC), prostate (PC) and liver (LC) cancers  are indicated as well as 
the age at diagnosis. Diagonal slash indicates deceased, while the proband is indicated with an arrow.
Results and discussion
Molecular analysis in the patient identified a heterozygous 
BRCA2 nucleotide mutation c.6428 C>A in exon 11. 
This variation introduces a nonsense mutation changing 
amino acid 2143 from serin to stop codon (Figure 2). 
To our best knowledge, this mutation was never reported 
before in the Breast Cancer information Core database 
(BIC; http://research.nhgri.nih.gov/bic/), or other 
resources. The two protein prediction programmes used 
to predict the functional consequence of  the BRCA2 
p.Ser2143Stop  mutation estimated  it to be pathogenic 
[14,15].
Hereditary breast and ovarian cancer syndrome is an 
autosomal dominant inherited cancer-susceptibility 
syndrome. This syndrome is characterised by multiple 
family members with breast or ovarian cancer or both, 
the presence of  both breast and ovarian cancer in a 
single individual, and early age of  breast cancer onset 
[16]. Approximately 10% of  cases of  ovarian cancer 
and 3-5% of  cases of  breast cancer are known to be 
associated with germline mutations in BRCA1 and 
BRCA2 [4, 5]. Male breast cancer is rare, with the peak 
age of  onset at 71 years. BRCA2 mutations are more 
frequent than BRCA1 with 15-20% of  cases giving a 
family history [17]. A male BRCA2 carrier has a 6% 
lifetime risk of  developing the disease, compared with 
0.1% in the normal population [18]. 
Recently in Morocco, our group and others local genetic 
centers, have developed oncogenetic consultation for 
familial forms of  breast and ovarian cancers. These 
centers offer currently genetic testing for BRCA1 and 
BRCA2 genes, and mutational profile of  these genes 
is becoming better known in Moroccan population 
[19, 20]. Even more, recently some healthy Moroccan 
females with a high risk of  developing breast cancer 
benefited from presymptomatic diagnosis for a 
preventive management [19]. In morocco, there is a 
national program against cancer that does not include 
actually a national genetic counseling and testing 
program for the familial mutations and polymorphisms 
which are common among the Moroccan population. 
In this study, we have identified a novel nonsense 
germline mutation of  BRCA2 gene in a man with breast 
cancer and family history.  This mutation is considered to 
be deleterious using in silico analysis. In practice for this 
family, we are enabled to offer a genetic councelling and 
to conduct DNA testing for presymptomatic diagnosis 
in healthy major men and women at risk if  they will 
request it. This will allow us to introduce supervision 
of  asymptomatic carriers in order to prevent and early 
diagnosis breast cancer in this family. More generally, 
the identification of  this new mutation will allow to 
enrich the Moroccan Human Mutation Database that 
lists mutations reported in the Moroccan population 
(MoHuMuDa; http://www.sante.gov.ma/Departements/
INH/MoHuMuDa/index.htm). This database was build up 
in 2007, and is devoted to the collection of  reported 
human mutations in Mendelian diseases identified in 
the native Moroccan population, or in patients from 
Moroccan origin living abroad. For each mutation 
disease, a specific table precise the name of  the gene, 
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Figure 2:  Electrophregram showing normal sequence (a) and the heterozygous c.6428 C>A of  BRCA2 gene 
causing the p.Ser2143Stop amino acid change (b).
the OMIM number of  the disease, the published DNA, 
and amino-acid change, the proper nomenclature, 
the number of  chromosomes, the frequency of  the 
mutation, and the source of  the data [21].
Theses mutations data could help, if  recurrent mutations 
in Moroccan patients are identified, to establish low 
cost public health strategies for molecular diagnosis of  
patients with hereditary breast cancer. The beneficial 
impact on the care and counseling of  individuals at risk 
is major, in order to reduce breast cancer mortality.
In summary, we here report a novel nonsense 
mutation of  BRCA2 gene in Moroccan case of  a man 
with familial breast cancer. Genetic screening is now 
offered to all family members.
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